Gamida Cell (NASDAQ:GMDA)

Executive Summary

Gamida Cell is an Israeli cell therapy company commercializing two FDA-approved products: OMISIRGE® (omidubicel) for hematopoietic stem cell transplantation in hematologic malignancies and severe aplastic anemia, and APHEXDA® (motixafortide) for stem cell mobilization in multiple myeloma. Leveraging its proprietary nicotinamide (NAM) enhancement technology, the company aims to improve outcomes for patients with blood cancers and non-malignant disorders. With a commercial-stage focus, Gamida Cell is transitioning from a development-stage biotech to a revenue-generating enterprise, facing the challenges of market adoption, reimbursement, and competition from established mobilization and transplant regimens.

Upcoming Catalysts (preview)

• Q4 2026OMISIRGE label expansion into additional hematologic malignancies or non-malignant indications45% success
• TBDAPHEXDA revenue growth acceleration driven by increased physician adoption and expanded access60% success
• Q3 2026Strategic partnership for NAM technology in autoimmune or genetic diseases30% success